ARGX Jun 2024 320.000 call
| Previous Close | 45.00 |
| Open | N/A |
| Bid | 64.70 |
| Ask | 69.40 |
| Strike | 320.00 |
| Expire Date | 2024-06-21 |
| Day's Range | 45.00 - 45.00 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 5 |
GlobeNewswireargenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024
R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and multifocal motor neuropathy (empasiprubart) that support advancement to Phase 3 development Next wave of innovative pipeline candidates to be introduced highlighting long-term commitment to transform autoimmunity Decision to not advance development of efgartigimod in PC-POTS based on Phase 2 ALPHA data June 17, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a glob
- GlobeNewswire
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of management will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024 at 2:40 PM ET in Miami, FL. A live webcast of the fireside chat may be accessed on the Investors section of the argenx website at argenx.com/inv
Investor's Business DailyAfter Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."
